BERKELEY, Calif. (AP) _ Aduro Biotech Inc. (ADRO) on Tuesday reported a loss of $24.5 million in its third quarter.
The Berkeley, California-based company said it had a loss of 33 cents per share.
The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was also for a loss of 33 cents per share.
The drug developer posted revenue of $3.8 million in the period, which fell short of Street forecasts. Three analysts surveyed by Zacks expected $4.2 million.
Aduro Biotech shares have dropped 30 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $7.95, a drop of 26 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ADRO at https://www.zacks.com/ap/ADRO